search
Back to results

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection (PROBE2)

Primary Purpose

HIV Infection

Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Rilpivirine + darunavir/cobicistat
Sponsored by
A.O. Ospedale Papa Giovanni XXIII
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infection focused on measuring Switch therapy, HIV, Dual ART, Rilpivirine, Darunavir/cobicistat, NNRTI, PI, virologically suppressed patients

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Written signed and dated informed consent to participate in the study must be given by the subject, in accordance with the International Conference of Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E627 and applicable regulations, before completing any procedure related to the study.
  2. HIV-1 documented infection
  3. Male and female subjects > 18 years of age.
  4. Males, or non-pregnant, non-lactating females of childbearing potential, as demonstrated by a negative pregnancy test, who agree to comply with any applicable contraceptive requirements of the protocol. Women of child-bearing potential with a negative pregnancy test at Screening and Day 1 should agree to use one of the following methods: Complete abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IMP, throughout the study, and for at least 2 weeks after; Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide) IUD and male condom Male partner sterilization confirmed and male condom Approved hormonal contraception and male condom Any other method with published data showing that the expected failure rate is <1% per year and use male condo Any contraception method must be used for at least 2 weeks after discontinuation of IMP.
  5. Being on a stable therapy for at least 6 months.
  6. SBR must be based on any 2NRTI plus a third NNRTI, PI or INI agent. Any possible registered drug is allowed among NRTI (e.g. tenofovir, lamivudine, emtricitabine and abacavir), PI (e.g. lopinavir, atazanavir, darunavir), NNRTI (efavirenz, nevirapine, rilpivirine) or INI (raltegravir, elvitegravir, dolutegravir).
  7. Having a fully suppressed HIV replication as documented by 2 prior HIV-RNA tests (at least two months apart) below the detection limit (50 copies/ml).
  8. Subjects and investigator must agree that participation in this study is in the best interest of the subject.

Exclusion Criteria:

  1. Patients co-infected with HBV
  2. Pregnancy or breast feeding.
  3. Positive anamnesis for allergy to NNRTI
  4. A positive historical genotypic test showing resistance-inducing mutation either toward NNRTIs or PIs
  5. History or other evidence of severe illness (malignancy or OI) requiring active treatment and/or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
  6. Anticipated need for Hepatitis C virus (HCV) therapy during the study period
  7. Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses
  8. All conditions and medicinal products listed in contraindications of DRV/c and rilpivirine
  9. Subjects with current or prior (previous year) history of alcohol or other substance abuse.
  10. Patients who have previously been screened for or enrolled into this study and subsequently withdrawn.
  11. Patients having been given investigational drugs within 12 weeks prior to screening.
  12. Inability or unwillingness to provide informed consent.
  13. Life expectancy < 18 months

Sites / Locations

  • Antiviral Therapy Unit, Ospedali Riuniti

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

RPV +DRV/cobi

baseline therapy (CAR)

Arm Description

The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.

The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).

Outcomes

Primary Outcome Measures

clinical response
proportion of patients with HIV-RNA < 50 copies/ml (FDA snapshot)
Virological response
proportion of patients with HIV-RNA > 50 copies/ml (FDA snapshot)
clinical response
proportion of patients with HIV-RNA < 50 copies/ml

Secondary Outcome Measures

Tolerability (number and proportion of AEs)
AEs total, drug related and leading to treatment interruption/change
Tolerability (number and proportion of AEs)
AEs total, drug related and leading to treatment interruption/change
Bone mineral density
change in bone stiffness
Bone mineral density
change in bone stiffness

Full Information

First Posted
August 13, 2019
Last Updated
August 19, 2019
Sponsor
A.O. Ospedale Papa Giovanni XXIII
Collaborators
San Raffaele University Hospital, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT04064632
Brief Title
RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection
Acronym
PROBE2
Official Title
Multicenter, National, Prospective, Open Label, Randomized, Pilot, Proof-of-concept Study on the Use of Rilpivirine Plus Darunavir/Cobicistat as Substitutive Agents in Virologic Suppressed Patients
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
February 1, 2017 (Actual)
Primary Completion Date
June 13, 2019 (Actual)
Study Completion Date
November 30, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
A.O. Ospedale Papa Giovanni XXIII
Collaborators
San Raffaele University Hospital, Italy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates efficacy and safety of rilpivirine as substitutive agent for the nucleosidic backbone of HAART in virologic suppressed patients when combined with cobicistat-boosted darunavir.
Detailed Description
HAART is generally based on the combination of three active drugs. Two of them, usually defined the backbone, belong to the nucleosidic analogues class (NRTI). In the last years, drugs of this class have been associated to several long-term adverse events of HAART such as lipoatrophy, cardiovascular diseases, bone and kidney toxicity. Furthermore the need of a triple drug regimen has recently been questioned as maintenance therapy in well controlled chronically treated subjects. In this setting, less drug regimens (LDR) have been proposed. LDR would allow a reduced exposure to drugs and eventually limit drug-drug interactions, drug-related toxicities and would allow treatment simplification so to enhance HAART acceptability, tolerability and persistence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infection
Keywords
Switch therapy, HIV, Dual ART, Rilpivirine, Darunavir/cobicistat, NNRTI, PI, virologically suppressed patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Patients are randomly allocated into two arms: The control arm continues the baseline therapy based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine and cobicistat/darunavir co-formulated tablets (a tablet day). The experimental arm receives rilpivirine and cobicistat/darunavir coformulated tablets at randomization.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1609 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RPV +DRV/cobi
Arm Type
Experimental
Arm Description
The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.
Arm Title
baseline therapy (CAR)
Arm Type
Active Comparator
Arm Description
The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).
Intervention Type
Drug
Intervention Name(s)
Rilpivirine + darunavir/cobicistat
Intervention Description
Switch to a dual ART
Primary Outcome Measure Information:
Title
clinical response
Description
proportion of patients with HIV-RNA < 50 copies/ml (FDA snapshot)
Time Frame
24 weeks
Title
Virological response
Description
proportion of patients with HIV-RNA > 50 copies/ml (FDA snapshot)
Time Frame
24 weeks
Title
clinical response
Description
proportion of patients with HIV-RNA < 50 copies/ml
Time Frame
48 weeks
Secondary Outcome Measure Information:
Title
Tolerability (number and proportion of AEs)
Description
AEs total, drug related and leading to treatment interruption/change
Time Frame
24 weeks
Title
Tolerability (number and proportion of AEs)
Description
AEs total, drug related and leading to treatment interruption/change
Time Frame
48 weeks
Title
Bone mineral density
Description
change in bone stiffness
Time Frame
24 weeks
Title
Bone mineral density
Description
change in bone stiffness
Time Frame
48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written signed and dated informed consent to participate in the study must be given by the subject, in accordance with the International Conference of Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E627 and applicable regulations, before completing any procedure related to the study. HIV-1 documented infection Male and female subjects > 18 years of age. Males, or non-pregnant, non-lactating females of childbearing potential, as demonstrated by a negative pregnancy test, who agree to comply with any applicable contraceptive requirements of the protocol. Women of child-bearing potential with a negative pregnancy test at Screening and Day 1 should agree to use one of the following methods: Complete abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IMP, throughout the study, and for at least 2 weeks after; Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide) IUD and male condom Male partner sterilization confirmed and male condom Approved hormonal contraception and male condom Any other method with published data showing that the expected failure rate is <1% per year and use male condo Any contraception method must be used for at least 2 weeks after discontinuation of IMP. Being on a stable therapy for at least 6 months. SBR must be based on any 2NRTI plus a third NNRTI, PI or INI agent. Any possible registered drug is allowed among NRTI (e.g. tenofovir, lamivudine, emtricitabine and abacavir), PI (e.g. lopinavir, atazanavir, darunavir), NNRTI (efavirenz, nevirapine, rilpivirine) or INI (raltegravir, elvitegravir, dolutegravir). Having a fully suppressed HIV replication as documented by 2 prior HIV-RNA tests (at least two months apart) below the detection limit (50 copies/ml). Subjects and investigator must agree that participation in this study is in the best interest of the subject. Exclusion Criteria: Patients co-infected with HBV Pregnancy or breast feeding. Positive anamnesis for allergy to NNRTI A positive historical genotypic test showing resistance-inducing mutation either toward NNRTIs or PIs History or other evidence of severe illness (malignancy or OI) requiring active treatment and/or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study. Anticipated need for Hepatitis C virus (HCV) therapy during the study period Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses All conditions and medicinal products listed in contraindications of DRV/c and rilpivirine Subjects with current or prior (previous year) history of alcohol or other substance abuse. Patients who have previously been screened for or enrolled into this study and subsequently withdrawn. Patients having been given investigational drugs within 12 weeks prior to screening. Inability or unwillingness to provide informed consent. Life expectancy < 18 months
Facility Information:
Facility Name
Antiviral Therapy Unit, Ospedali Riuniti
City
Bergamo
ZIP/Postal Code
24128
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35485333
Citation
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial. Antivir Ther. 2021 May;26(3-5):51-57. doi: 10.1177/13596535211042226. Epub 2021 Oct 27.
Results Reference
derived
PubMed Identifier
32129855
Citation
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). J Antimicrob Chemother. 2020 May 1;75(5):1332-1337. doi: 10.1093/jac/dkaa018.
Results Reference
derived

Learn more about this trial

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

We'll reach out to this number within 24 hrs